MX2016000794A - Composiciones farmaceuticas de pancreatina de potencia alta. - Google Patents

Composiciones farmaceuticas de pancreatina de potencia alta.

Info

Publication number
MX2016000794A
MX2016000794A MX2016000794A MX2016000794A MX2016000794A MX 2016000794 A MX2016000794 A MX 2016000794A MX 2016000794 A MX2016000794 A MX 2016000794A MX 2016000794 A MX2016000794 A MX 2016000794A MX 2016000794 A MX2016000794 A MX 2016000794A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
high potency
pancreatin
pancreatin pharmaceutical
compositions
Prior art date
Application number
MX2016000794A
Other languages
English (en)
Inventor
Boltri Luigi
Ghidorsi Luigi
Pironti Vincenza
Becker Robert
Arzuffi Paola
Original Assignee
Allergan Pharmaceuticals Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52117920&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016000794(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Pharmaceuticals Int Ltd filed Critical Allergan Pharmaceuticals Int Ltd
Publication of MX2016000794A publication Critical patent/MX2016000794A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/94—Pancreatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Abstract

La presente invención provee composiciones farmacéuticas de potencia alta que comprenden enzimas pancreatina de actividad alta. La invención también está dirigida a un proceso de producción de enzimas pancreatina-AA y sus composiciones o formas de dosificación, y métodos para su uso.
MX2016000794A 2013-07-22 2014-07-15 Composiciones farmaceuticas de pancreatina de potencia alta. MX2016000794A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361856952P 2013-07-22 2013-07-22
PCT/IB2014/002583 WO2015019198A2 (en) 2013-07-22 2014-07-15 High potency pancreatin pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX2016000794A true MX2016000794A (es) 2016-12-02

Family

ID=52117920

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000794A MX2016000794A (es) 2013-07-22 2014-07-15 Composiciones farmaceuticas de pancreatina de potencia alta.

Country Status (13)

Country Link
US (1) US20160152968A1 (es)
EP (1) EP3024479B2 (es)
JP (1) JP2016527247A (es)
KR (1) KR20160055123A (es)
CN (1) CN105392496A (es)
AU (1) AU2014304176A1 (es)
BR (1) BR112016001289A2 (es)
CA (1) CA2919114A1 (es)
ES (1) ES2743212T5 (es)
IL (1) IL243627A (es)
MX (1) MX2016000794A (es)
RU (1) RU2686460C2 (es)
WO (1) WO2015019198A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
CA2677989C (en) 2007-02-20 2018-04-24 Eurand Pharmaceuticals Limited Stable digestive enzyme compositions
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
MX348118B (es) 2010-10-01 2017-05-26 Aptalis Pharma Ltd Formulaciones de pancrelipasa con recubrimiento enterico de baja potencia.
EP2987499B1 (en) 2011-08-08 2019-05-08 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
RU2679832C2 (ru) 2013-08-09 2019-02-13 Аллерган Фармасьютикалз Интернэйшнл Лимитед Композиция пищеварительных ферментов, подходящая для энтерального введения
ES2834483T3 (es) * 2013-11-05 2021-06-17 Allergan Pharmaceuticals Int Ltd Composiciones farmacéuticas de pancreatina de alta potencia
US11278603B2 (en) 2016-03-28 2022-03-22 Abbvie Inc. Enzyme compositions with reduced viral and microbial contamination
PT3436055T (pt) * 2016-03-28 2024-01-29 Abbott Laboratories Gmbh Composições enzimáticas com uma reduzida contaminação viral e microbiana
WO2019067743A1 (en) * 2017-09-27 2019-04-04 Abbvie Inc. ENZYME COMPOSITIONS HAVING MICROBIAL CONTAMINATION AND REDUCED VIRAL
CN111394275B (zh) * 2020-02-22 2022-05-27 华东师范大学 一株解淀粉芽孢杆菌及其应用、水产饲料和水产养殖方法
FR3111559A1 (fr) * 2020-06-18 2021-12-24 Azurrx Biopharma, Inc. Formulations non porcines et leurs procédés

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB928654A (en) 1960-10-25 1963-06-12 Philips Nv Improvements in or relating to the production of pancreatin
US3168448A (en) 1963-01-07 1965-02-02 Wilson & Co Inc Process of preparing a lipolytic enzyme composition
EP0115023B1 (de) * 1982-12-30 1988-07-27 Nordmark Arzneimittel GmbH Verfahren zur Gewinnung von Pankreatin
DK173590D0 (da) * 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
CA2222682A1 (en) 1995-05-31 1996-12-05 Medzyme N.V. Composition to improve digestibility and utilisation of nutrients
KR19990072826A (ko) * 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
US20010046493A1 (en) 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
CA2419572A1 (en) * 2003-02-18 2004-08-18 Axcan Pharma Inc. High dosage protease formulation
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US7718169B2 (en) 2004-10-14 2010-05-18 Cystic Fibrosis Foundations Therapeutics, Inc. Compositions and methods for treating pancreatic insufficiency
RU2445952C2 (ru) * 2007-02-20 2012-03-27 Юранд Фармасьютикалз Лимитед Стабильные композиции пищеварительных ферментов
CN102884181A (zh) * 2010-03-19 2013-01-16 加拿大阿普塔利斯制药公司 用于药用胰腺酶制剂中的病毒灭活的β-丙内酯
JP2013071929A (ja) * 2011-09-29 2013-04-22 Kobayashi Pharmaceutical Co Ltd 胃腸薬
ES2834483T3 (es) 2013-11-05 2021-06-17 Allergan Pharmaceuticals Int Ltd Composiciones farmacéuticas de pancreatina de alta potencia

Also Published As

Publication number Publication date
CN105392496A (zh) 2016-03-09
KR20160055123A (ko) 2016-05-17
WO2015019198A3 (en) 2015-05-28
EP3024479A2 (en) 2016-06-01
JP2016527247A (ja) 2016-09-08
AU2014304176A1 (en) 2016-02-11
ES2743212T5 (es) 2023-04-25
RU2016101760A (ru) 2017-08-28
CA2919114A1 (en) 2015-02-12
RU2686460C2 (ru) 2019-04-26
EP3024479B1 (en) 2019-06-05
EP3024479B2 (en) 2023-02-08
ES2743212T3 (es) 2020-02-18
RU2016101760A3 (es) 2018-05-14
IL243627A0 (en) 2016-03-31
IL243627A (en) 2017-12-31
BR112016001289A2 (pt) 2018-03-20
WO2015019198A2 (en) 2015-02-12
US20160152968A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
AU2018236800B2 (en) DNA-PK inhibitors
MX2016000480A (es) Composiciones farmaceuticas de pancreatina de alta potencia.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2019015744A (es) Composiciones farmaceuticas.
MX2016008448A (es) Conjugados de var2csa-farmaco.
IN2014DN08867A (es)
IN2015KN00262A (es)
WO2014153346A8 (en) Engineering a heterogeneous tissue from pluripotent stem cells
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
PH12017501095A1 (en) Piperidine derivatives as hdac1/2 inhibitors
MX2019000536A (es) Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
GEP201706621B (en) Benzamides
MX2016002998A (es) Derivados novedosos de ftalazinona y su procedimiento de fabricacion.
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
NZ710291A (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2013011694A (es) Analogos de taxano y abeo-taxanos.
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
MX2016005545A (es) Analogo de la relaxina humana, composicion farmaceutica del mismo y aplicacion farmaceutica del mismo.
MX2015016603A (es) Composiciones de corticosteroides.
IN2014DN03010A (es)